Share this article
Share this article
SAN CARLOS, Calif. and BOULDER, Colo., May 26, 2021 /PRNewswire/ Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, and Addario Lung Cancer Medical Institute (ALCMI) today announced they will present on the progress of Biomarker Analysis in High PD-L1 Expressing NSCLC Patients Treated With PD-1/PD-L1 Based Therapy With or Without the Addition of Platinum Based Chemotherapy (BEACON-Lung). The BEACON-Lung study aims to evaluate biomarkers to predict overall survival and early progression outcomes in treatment-naïve advanced stage non-small cell lung cancer (NSCLC) patients with high PD-L1 expression. The first patient participant enrolled in the study this week.
E-Mail
IMAGE: HPV infection causes cells to undergo changes. If not treated these cells can, over time, become cancer cells. view more
Credit: National Cancer Institute
Today, doctors and scientists across America at National Cancer Institute (NCI)-designated cancer centers and other organizations issued a joint statement urging the nation s health care systems, physicians, parents and children, and young adults to get the human papillomavirus (HPV) vaccination back on track.
Dramatic drops in annual well visits and immunizations during the COVID-19 pandemic have caused a significant vaccination gap and lag in vital preventive services among U.S. children and adolescents especially for the HPV vaccine. The pandemic also has exacerbated health disparities, leaving Black, Indigenous and other people of color; rural; and sexual minority adolescents at even greater risk for missed doses of this cancer prevention vaccine.
COLUMBUS, Ohio - Up to 38.6% of people with colon cancer who have a hereditary cancer syndrome including 6.3% of those with Lynch syndrome could have.
Michael Faber, New VP of Advancement for Wexner Medical Center, health sciences colleges
May 17, 2021
Faber joins Ohio State from the University of California, San Francisco (UCSF), where he is the associate vice chancellor of University Development & Alumni Relations. While at UCSF, Faber has distinguished himself as one of the nation’s top development leaders in the health sciences. He was charged with raising more than $500 million annually with a $47 million operating budget. His team serves biomedical research units, basic science departments, and all adult clinical specialties for the UCSF School of Medicine and its affiliated medical center. Earlier in his career, Faber served in strategy and advancement roles at the Massachusetts Institute of Technology and Harvard University.